Mireca and Graybug Terminate Partnership Agreement

Mireca Medicines announced the termination of the partnership agreement between Mireca and Graybug, now known as CalciMedica. The termination was prompted by CalciMedica's decision to shift its focus on drug development away from ocular diseases.

In light of the termination, all intellectual property rights that were previously sold by Mireca to Graybug have now been reassigned to Mireca. Additionally, as stated in a news release by Mireca, an additional patent application safeguarding specific cyclic guanosine monophosphate (cGMP)-analogs within Graybug's sustained-release drug delivery technology has been (re)assigned to Mireca.

"Under the terms of this agreement, ownership of all formulation and release data for select cGMP-analogs in Graybug’s sustained-release drug delivery technologies, as protected in a new patent application, was also assigned to Mireca. Furthermore, an improved, patent protected cGMP-analog was selected as the lead compound and a new, proprietary manufacturing process conforming to the standards of good-manufacturing practice (GMP) was developed. Various cGMP-analog salt forms produced with this new manufacturing process are now also owned by Mireca," Mireca stated in the news release.

"After this fruitful period of external collaborative development with Graybug, Mireca will continue the development of the new lead compound and formulation combination, now designated as MM238, as internal lead product. The focus for MM238 drug development continues to be the treatment of inherited retinal diseases (IRDs), such as retinitis pigmentosa, Leber’s congenital amaurosis, and Stargardt’s disease,” the company added.

“During the partnership with Graybug, some major advancements were achieved for Mireca’s cGMP-analogs on the path toward potential treatments for patients suffering from IRDs. It feels so good to be reunited with our value-added lead product MM238. It fills us with energy and confidence for its further development. We have increased our partnering and fundraising efforts to fully capitalize on the potential of our compounds in IRDs and other neurodegenerative diseases," said Barbara Brunnhuber, Chief Executive Officer of Mireca.